Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

"It is erdafitinib’s time to shine," says Arlene O. Siefker-Radtke, MD.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

“The ADVANCED-2 trial in NMIBC is an exciting opportunity to build on the favorable anti-tumor and safety data of TARA-002 presented earlier this year," says Gautam Jayram, MD.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

The first patient with NMIBC has been dosed with nadofaragene firadenovec-vncg as part of the Adstiladrin Early Experience Program.

BT8009 targets the tumor antigen Nectin-4, which has elevated expression levels in urothelial cancer.